{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypercortisolemia&page=2",
    "query": {
      "condition": "Hypercortisolemia",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 87,
    "total_pages": 9,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypercortisolemia&page=3&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Hypercortisolemia&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-29T22:27:56.912Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02180217",
      "title": "Safety and Efficacy of LCI699 for the Treatment of Patients With Cushing's Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cushings Disease"
      ],
      "interventions": [
        {
          "name": "osilodrostat",
          "type": "DRUG"
        },
        {
          "name": "LCI699 matching placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 137,
      "start_date": "2014-10-06",
      "completion_date": "2019-12-04",
      "has_results": true,
      "last_update_posted_date": "2021-01-06",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 12,
      "location_summary": "Aurora, Colorado • Atlanta, Georgia • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02180217"
    },
    {
      "nct_id": "NCT07138274",
      "title": "Metyrapone Study for Patients Diagnosed With Mild Autonomous Cortisol Secretion - MACS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Mild Autonomous Cortisol Secretion (MACS)",
        "Autonomous Cortisol Secretion (ACS)"
      ],
      "interventions": [
        {
          "name": "Metyrapone 250 mg Oral Tablets",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 90,
      "start_date": "2026-10",
      "completion_date": "2031-12",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07138274"
    },
    {
      "nct_id": "NCT04840342",
      "title": "MR Antagonist and LSD1",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Hypertension",
        "Mineralocorticoid Excess"
      ],
      "interventions": [
        {
          "name": "Eplerenone",
          "type": "DRUG"
        },
        {
          "name": "Amlodipine",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "17 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "17 Years and older"
      },
      "enrollment_count": 300,
      "start_date": "2022-02-03",
      "completion_date": "2025-12-15",
      "has_results": false,
      "last_update_posted_date": "2026-10-01",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04840342"
    },
    {
      "nct_id": "NCT00796783",
      "title": "A Study to Confirm Recurrent or Persistent Cushing's Syndrome in Patients With Signs or Symptoms of Hypercortisolemia",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cushing's Syndrome"
      ],
      "interventions": [
        {
          "name": "Cushing's syndrome confirmation",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2009-02",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2014-06-20",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 3,
      "location_summary": "Escondido, California • Hollywood, Florida • San Antonio, Texas",
      "locations": [
        {
          "city": "Escondido",
          "state": "California"
        },
        {
          "city": "Hollywood",
          "state": "Florida"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00796783"
    },
    {
      "nct_id": "NCT05030545",
      "title": "Cardiovascular Manifestations of MR Activation in Primary Aldosteronism: Pilot Clinical Study",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Primary Aldosteronism",
        "Hypertension"
      ],
      "interventions": [
        {
          "name": "Eplerenone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Brigham and Women's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 40,
      "start_date": "2022-12-15",
      "completion_date": "2028-02-28",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05030545"
    },
    {
      "nct_id": "NCT00004343",
      "title": "Study of Hypercortisolism in Cushing's Syndrome and Stress-Induced Pseudo-Cushing's Syndrome",
      "overall_status": "UNKNOWN",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Cushing's Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Center for Research Resources (NCRR)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "0 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "0 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "1999-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2005-06-24",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 1,
      "location_summary": "Portland, Oregon",
      "locations": [
        {
          "city": "Portland",
          "state": "Oregon"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00004343"
    },
    {
      "nct_id": "NCT01431326",
      "title": "Pharmacokinetics of Understudied Drugs Administered to Children Per Standard of Care",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Adenovirus",
        "Anesthesia",
        "Anxiety",
        "Anxiolysis",
        "Autism",
        "Autistic Disorder",
        "Bacterial Meningitis",
        "Bacterial Septicemia",
        "Benzodiazepine",
        "Bipolar Disorder",
        "Bone and Joint Infections",
        "Central Nervous System Infections",
        "Convulsions",
        "Cytomegalovirus Retinitis",
        "Early-onset Schizophrenia Spectrum Disorders",
        "Epilepsy",
        "General Anesthesia",
        "Gynecologic Infections",
        "Herpes Simplex Virus",
        "Infantile Hemangioma",
        "Infection",
        "Inflammation",
        "Inflammatory Conditions",
        "Intra-abdominal Infections",
        "Lower Respiratory Tract Infections",
        "Migraines",
        "Pain",
        "Pneumonia",
        "Schizophrenia",
        "Sedation",
        "Seizures",
        "Skeletal Muscle Spasms",
        "Skin and Skin-structure Infections",
        "Treatment-resistant Schizophrenia",
        "Urinary Tract Infections",
        "Withdrawal",
        "Sepsis",
        "Gram-negative Infection",
        "Bradycardia",
        "Cardiac Arrest",
        "Cardiac Arrhythmia",
        "Staphylococcal Infections",
        "Nosocomial Pneumonia",
        "Neuromuscular Blockade",
        "Methicillin Resistant Staphylococcus Aureus",
        "Endocarditis",
        "Neutropenia",
        "Headache",
        "Fibrinolytic Bleeding",
        "Pulmonary Arterial Hypertension",
        "CMV Retinitis",
        "Hypertension",
        "Chronic Kidney Diseases",
        "Hyperaldosteronism",
        "Hypokalemia",
        "Heart Failure",
        "Hemophilia",
        "Heavy Menstrual Bleeding",
        "Insomnia"
      ],
      "interventions": [
        {
          "name": "The POPS study is collecting PK data on children prescribed the following drugs of interest per standard of care:",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Daniel Benjamin",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "21 Years",
        "sex": "ALL",
        "summary": "Up to 21 Years"
      },
      "enrollment_count": 3520,
      "start_date": "2011-11",
      "completion_date": "2019-11",
      "has_results": false,
      "last_update_posted_date": "2023-09-06",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 43,
      "location_summary": "Anchorage, Alaska • Little Rock, Arkansas • La Jolla, California + 37 more",
      "locations": [
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01431326"
    },
    {
      "nct_id": "NCT01897727",
      "title": "Etiology of Sleep Apnea-related Hyperaldosteronism - BP Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obstructive Sleep Apnea",
        "Resistant Hypertension",
        "Hyperaldosteronism"
      ],
      "interventions": [
        {
          "name": "Spironolactone",
          "type": "DRUG"
        },
        {
          "name": "BP medication uptitration",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "19 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "19 Years to 80 Years"
      },
      "enrollment_count": 41,
      "start_date": "2009-01",
      "completion_date": null,
      "has_results": true,
      "last_update_posted_date": "2014-01-15",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01897727"
    },
    {
      "nct_id": "NCT06106295",
      "title": "Metyrapone for Mild Autonomous Cortisol Secretion (MACS)",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Autonomous Cortisol Secretion",
        "Mild Autonomous Cortisol Secretion (MACS)"
      ],
      "interventions": [
        {
          "name": "Metyrapone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 30,
      "start_date": "2023-12-19",
      "completion_date": "2028-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-25",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06106295"
    },
    {
      "nct_id": "NCT05307328",
      "title": "SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Cushing's Syndrome I",
        "Cushing Disease Due to Increased ACTH Secretion",
        "Cortisol Excess",
        "Cortisol; Hypersecretion",
        "Cortisol Overproduction",
        "Ectopic ACTH Secretion"
      ],
      "interventions": [
        {
          "name": "SPI-62",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sparrow Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 26,
      "start_date": "2022-09-01",
      "completion_date": "2025-08-01",
      "has_results": false,
      "last_update_posted_date": "2025-10-08",
      "last_synced_at": "2026-10-29T22:27:56.912Z",
      "location_count": 8,
      "location_summary": "Phoenix, Arizona • Fort Myers, Florida • Rochester, Minnesota + 5 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Henderson",
          "state": "Nevada"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05307328"
    }
  ]
}